GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP trimmed its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 65.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,577 shares of the company's stock after selling 106,095 shares during the quarter. Bridgewater Associates LP's holdings in GE HealthCare Technologies were worth $5,310,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its holdings in GE HealthCare Technologies by 12.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,710,938 shares of the company's stock valued at $254,422,000 after purchasing an additional 290,019 shares in the last quarter. Van ECK Associates Corp purchased a new position in GE HealthCare Technologies in the 3rd quarter valued at about $208,513,000. FMR LLC boosted its holdings in GE HealthCare Technologies by 4.1% in the 3rd quarter. FMR LLC now owns 2,165,826 shares of the company's stock worth $203,263,000 after buying an additional 84,411 shares during the last quarter. Swiss National Bank increased its stake in GE HealthCare Technologies by 0.5% during the 3rd quarter. Swiss National Bank now owns 1,287,187 shares of the company's stock worth $120,802,000 after buying an additional 6,500 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of GE HealthCare Technologies by 18.0% during the second quarter. The Manufacturers Life Insurance Company now owns 1,245,961 shares of the company's stock valued at $97,088,000 after acquiring an additional 189,956 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.

GE HealthCare Technologies Trading Up 0.3 %

NASDAQ:GEHC traded up $0.22 on Friday, reaching $83.22. The company's stock had a trading volume of 1,277,723 shares, compared to its average volume of 3,071,344. GE HealthCare Technologies Inc. has a 12-month low of $66.39 and a 12-month high of $94.55. The stock has a 50 day moving average price of $87.78 and a 200 day moving average price of $83.62. The firm has a market cap of $38.02 billion, a price-to-earnings ratio of 22.86, a price-to-earnings-growth ratio of 2.97 and a beta of 1.24. The company has a quick ratio of 0.98, a current ratio of 1.23 and a debt-to-equity ratio of 1.12.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.08. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The firm had revenue of $4.86 billion for the quarter, compared to analyst estimates of $4.87 billion. During the same period in the previous year, the firm earned $0.99 EPS. GE HealthCare Technologies's revenue was up .9% on a year-over-year basis. On average, equities analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 EPS for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Tuesday, January 14th will be paid a dividend of $0.035 per share. The ex-dividend date is Tuesday, January 14th. This is a positive change from GE HealthCare Technologies's previous quarterly dividend of $0.03. This represents a $0.14 dividend on an annualized basis and a yield of 0.17%. GE HealthCare Technologies's dividend payout ratio is 3.85%.

Insiders Place Their Bets

In other news, CEO Roland Rott sold 3,577 shares of GE HealthCare Technologies stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now directly owns 24,298 shares of the company's stock, valued at approximately $2,101,291.04. The trade was a 12.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.27% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts recently commented on GEHC shares. Evercore ISI boosted their price target on GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. UBS Group lowered shares of GE HealthCare Technologies from a "neutral" rating to a "sell" rating and dropped their target price for the stock from $84.00 to $74.00 in a report on Thursday, September 26th. JPMorgan Chase & Co. initiated coverage on shares of GE HealthCare Technologies in a research note on Monday, September 9th. They issued a "neutral" rating and a $90.00 price target on the stock. BTIG Research raised shares of GE HealthCare Technologies from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research note on Wednesday, September 18th. Finally, Wells Fargo & Company increased their price objective on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the company an "overweight" rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $94.36.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.